Cullinan Therapeutics, Inc.
CGEM · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | — | — | 144.65M | 111.21M | 2.46 |
| 2023 FY | — | — | -191.09M | -153.16M | -3.69 |
| 2024 FY | — | -306.00K | -196.92M | -167.38M | -3.11 |
| 2025 FY | — | — | -241.65M | -219.88M | -3.72 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 561.12M | 26.09M | 156.15M | 5.19M | 535.03M |
| 2023 FY | 484.18M | 30.29M | 98.43M | 3.59M | 453.70M |
| 2024 FY | 621.82M | 31.50M | 83.01M | 2.15M | 590.33M |
| 2025 FY | 448.37M | 39.64M | 88.33M | 2.68M | 408.73M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -126.66M | -1.13M | -127.80M | — | 96.38M |
| 2023 FY | -134.28M | -208.00K | -134.48M | — | -57.72M |
| 2024 FY | -145.30M | — | -145.30M | — | -15.43M |
| 2025 FY | -175.75M | -49.00K | -175.80M | — | 5.33M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 476.48M | 325.52M | — | — | — |
| 2023 FY | 422.96M | 328.11M | — | — | — |
| 2024 FY | 654.93M | 574.08M | — | — | — |
| 2025 FY | 611.17M | 525.52M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | — | — | -75.80M | -70.06M | -1.19 |
| 2025 Q3 | — | — | -55.60M | -50.61M | -0.86 |
| 2025 Q4 | — | — | -55.26M | -50.71M | -0.86 |
| 2026 Q1 | — | -79.00K | -53.70M | -49.66M | -0.84 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 520.33M | 28.18M | 72.82M | 1.52M | 492.15M |
| 2025 Q3 | 484.13M | 32.76M | 103.34M | 1.19M | 451.37M |
| 2025 Q4 | 448.37M | 39.64M | 88.33M | 2.68M | 408.73M |
| 2026 Q1 | 402.98M | 36.81M | 75.08M | 2.38M | 366.17M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -57.61M | — | -57.61M | — | -3.84M |
| 2025 Q3 | -36.88M | — | -36.92M | — | 30.52M |
| 2025 Q4 | -38.11M | -11.00K | -38.12M | — | -15.00M |
| 2026 Q1 | -46.05M | — | -46.05M | — | -13.25M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 444.38M | 373.08M | — | — | — |
| 2025 Q3 | 349.96M | 247.81M | — | — | — |
| 2025 Q4 | 612.73M | 527.08M | — | — | — |
| 2026 Q1 | 841.25M | 768.55M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |